2018 American Transplant Congress
Performance of Molecular Diagnostic Algorithms of T-Cell Mediated Kidney Rejection (TCMR) in Non-Transplant Biopsies with Interstitial Nephritis
DNA microarray based tools for the diagnosis of TCMR have been developed and are now being offered commercially. There is need to further evaluate the…2018 American Transplant Congress
Receiving Hypertensive Donor Has an Inferior Prognosis in Simultaneous Liver Kidney Transplantation Recipient
Background: The impacts of hypertensive (HTN) donor on the prognosis of simultaneous liver kidney transplantation (SLKT) patient are not known to date, and an applicable…2018 American Transplant Congress
Modified Protocol for ABO-Incompatible Living Donor Liver Transplantation with Rituximab and Intravenous Immunoglobulin without Plasma Exchange
Center for Liver Cancer, National Cancer Center, Il-san Donggu, Goyang, Republic of Korea.
Purpose: Since a variety of desensitization strategies including rituximab, intravenous immunoglobulin (IVIG), and plasma exchange (PE) have been introduced, the survival and outcomes of recipients…2018 American Transplant Congress
Living Liver Donation is Safe in Donors Heterozygous for an alpha-1 Antitrypsin Gene Mutation
Patients homozygous for an alpha-1 antitrypsin mutation, particularly the Pi*ZZ phenotype, develop cirrhosis and pulmonary emphysema. Those with a heterozygous phenotype are thought to have…2018 American Transplant Congress
The Grade of Pre-Transplant Portal Vein Thrombosis in Liver Transplant Recipients Impacts Graft and Patient Survival
Henry Ford Transplant Institute, Henry Ford Health System, Detroit, MI.
Background: Portal vein thrombosis (PVT) in the pre-transplant (pretx) setting makes liver transplantation technically challenging and is also known to affect post transplant outcomes. Few…2018 American Transplant Congress
Outcomes of Donation after Cardiac Death Liver Grafts from Donors ≥ 50 Years of Age: A Multi-Center Analysis
Introduction:As the population in the United States continues to age, an increase in the number of potential DCD donors with advanced chronological age can be…2018 American Transplant Congress
De Novo Belatacept in Clinical Vascularized Composite Allotransplantation
Most immunosuppressive regimens in vascularized composite allotransplantation (VCA) have been calcineurin inhibitor (CNI)–based. Costimulation blockade has emerged as a replacement for CNI–based regimens in kidney…2018 American Transplant Congress
Depletion Resistant Effector Memory T Cells Mediate Thymoglobulin Refractory Allograft Rejection in Human Intestinal Transplant Recipients
Medstar Georgetown Transplant Institute, Medstar Georgetown University Hospital, Washington, DC.
A. This study aimed to determine the mechanisms underlying T cell depletion-resistant moderate to severe acute cellular rejection (ACR) in intestinal transplantation (ITx) patients.B. A…2018 American Transplant Congress
Ischemia Reperfusion Injury & Risk for Antibody Mediated Rejection (ABMR) in HLA Sensitized Patients Treated with C1 Esterase Inhibitor (C1INH)
Introduction: Ischemia reperfusion injury (IRI) contributes to delayed graft function (DGF). IRI/DGF in HLA-sensitized (HS) patients likely activates innate and memory injury pathways that may…2018 American Transplant Congress
Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study
1TRANSFORM Study Group, Livingston; 2Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Despite remarkable short-term survival benefits, long-term outcomes in kidney transplant recipients (KTRs) remain unsatisfactory. Everolimus (EVR) may improve long-term outcomes by reducing calcineurin inhibitor…
- « Previous Page
- 1
- …
- 186
- 187
- 188
- 189
- 190
- …
- 211
- Next Page »